Group 1 - The Hong Kong Innovative Drug ETF (513120) experienced a decline of 0.44% on December 1, with a trading volume of 3.824 billion yuan [1] - The fund's shares increased by 4 million, bringing the total shares to 18.690 billion, with a notable increase of 1.290 billion shares over the last 20 trading days [1] - The latest net asset value of the fund is calculated at 25.209 billion yuan [1] Group 2 - The performance benchmark for the Hong Kong Innovative Drug ETF is the return rate of the China Securities Hong Kong Innovative Drug Index (denominated in RMB) [1] - The fund is managed by Guangfa Fund Management Co., Ltd., with Liu Jie as the fund manager [1] - Since its inception on July 1, 2022, the fund has achieved a return of 34.87%, while the return over the past month is -0.55% [1]
12月1日港股创新药ETF（513120）份额增加400.00万份
Xin Lang Cai Jing·2025-12-02 01:05